PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 203 filers reported holding PDL BIOPHARMA INC in Q2 2015. The put-call ratio across all filers is 0.19 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $0 | – | 104 | +20.9% | 0.00% | – |
| Q1 2017 | $0 | – | 86 | -17.3% | 0.00% | – |
| Q4 2016 | $0 | -100.0% | 104 | -84.1% | 0.00% | – |
| Q3 2016 | $2,000 | 0.0% | 654 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $2,000 | 0.0% | 654 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $2,000 | 0.0% | 654 | +6.5% | 0.00% | 0.0% |
| Q4 2015 | $2,000 | -33.3% | 614 | +11.6% | 0.00% | 0.0% |
| Q3 2015 | $3,000 | -78.6% | 550 | -72.5% | 0.00% | -75.0% |
| Q1 2015 | $14,000 | -58.8% | 2,000 | -54.2% | 0.00% | -42.9% |
| Q4 2014 | $34,000 | -61.4% | 4,370 | -62.8% | 0.01% | -58.8% |
| Q3 2014 | $88,000 | -22.1% | 11,737 | +0.6% | 0.02% | -19.0% |
| Q2 2014 | $113,000 | +17.7% | 11,666 | +0.6% | 0.02% | +10.5% |
| Q1 2014 | $96,000 | +4.3% | 11,598 | +6.0% | 0.02% | +46.2% |
| Q4 2013 | $92,000 | -57.6% | 10,938 | -59.9% | 0.01% | -61.8% |
| Q3 2013 | $217,000 | +93.8% | 27,258 | +88.3% | 0.03% | +78.9% |
| Q2 2013 | $112,000 | – | 14,476 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
| AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
| Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
| GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
| Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
| Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
| Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
| RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
| SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |